Propofol is a novel, fast-acting, short-acting intravenous sedative-hypnotic that can be used for the induction and maintenance of general anesthesia. This study used a double-blind method to evaluate the effectiveness and safety of domestic Pofol and Diprivan for the management of total intravenous general anesthesia. This study was approved by the Clinical Research Committee of Seoul National University Hospital. Test drugs were anesthetized in a double-blind manner. 74 patients (aged 18-60 years old, operation time less than 2 hours) were induced anesthesia with 2 mg/kg test drug injection for 20 seconds, and then maintained anesthesia with continuous infusion of syringe pump. The infusion dose of the test drug during the maintenance of anesthesia was controlled to maintain +/-20% of the systolic blood pressure measured in the ward. In order to evaluate the efficacy of the drug, the induction dose, the average maintenance dose, the time to loss of consciousness after injection of the induction dose, and the time to awakening were measured or calculated. To evaluate the safety of the drug, pain after injection of the drug, the patient's recovery, and adverse events or side effects were recorded. Changes in blood pressure and heart rate were measured and arterial blood gases were analyzed during the perianesthesia period. There was no significant difference between the Pofol group (P) and the Diprivan group (D) in terms of gender, age, body weight, duration of anesthesia, and distribution of ASA physical status. Induction dose and mean maintenance dose did not differ between P and D (mean +SD, 121+/-25 mg and 0.213+/-0.064 mg/kg/min vs 125+/-27 mg and 0.233+/-0.058 ) respectively in mg/kg/min). P and 14 post-drug withdrawal time to loss of consciousness, reaction time and orientation time were 14 +/- 19 seconds, 10 minutes 2 seconds +/- 5 minutes 39 seconds, 17 minutes 16 seconds +/- 9 minutes 43 seconds D was + /-26 seconds, 12 minutes and 52 seconds +/-8 minutes and 42 seconds, 22 minutes and 47 seconds +/-14 minutes and 17 seconds. But there is no statistical difference between P and D respectively. The incidence of post-injection pain was 65.7% in group P and 52.7% in group D. The recovery from anesthesia was smooth, 82.9% in group P and 91.7% in group D. Adverse events during induction were recorded in four patients (apnea(1), opisthotonus(2) and hypotension(1) in P), and in two patients in D(apnea(1), bradycardia( 1)). The number of patients with adverse events during maintenance of anesthesia and post-anesthesia recovery with P and D was 8 patients. Although P and D had different adverse event profiles, there was no difference in the rates between the two drugs. These adverse events resolved without any specific treatment. In conclusion, there was no difference in efficacy and safety between Pofol and Diprivan.